当前位置: X-MOL 学术Acta Pharm. Sin. B › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection.
Acta Pharmaceutica Sinica B ( IF 14.7 ) Pub Date : 2020-04-28 , DOI: 10.1016/j.apsb.2020.04.013
Jingwei Bian 1, 2 , Rongsheng Zhao 3 , Suodi Zhai 3 , Zijian Li 2, 3
Affiliation  

•There is no enough evidence to indicate that ACEIs and ARBs result in ACE2 upregulation.•The level of ACE2 expression is not completely related with the risk of COVID-19 infection.•There is currently no evidence that ACEI/ARB increase risk for COVID-19 infection from clinical trials.•It is not recommended that COVID-19 patients with hypertension or normal hypertensive patients at risk for exposure to stop using ACEI/ARB or change to other antihypertensive drugs.

中文翻译:


致编辑的信:抗 RAS 药物和 SARS-CoV-2 感染。



•没有足够的证据表明ACEI和ARB会导致ACE2上调。•ACE2表达水平与COVID-19感染风险并不完全相关。•目前没有证据表明ACEI/ARB会增加COVID-19感染风险临床试验中-19感染。•不建议患有高血压的COVID-19患者或有暴露风险的正常高血压患者停止使用ACEI/ARB或改用其他降压药。
更新日期:2020-04-28
down
wechat
bug